Patrick W.
- Country
- Germany
- Department
- Neurodegenerative Erkrankung
Research Overview
- Evaluation of ALN-HTT02 in Adult Patients with Huntington's Disease
- Safety and Tolerability Evaluation of QRL-201 in Patients with Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
- Phase 1 Study on Safety, Pharmacokinetics, and Pharmacodynamics of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis Patients
Data & Insights
Has run more than one trial at 51 of 123 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in treating and researching neurodegenerative conditions, with particular emphasis on progressive neurological disorders that affect motor function and cognitive abilities.
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease
The research focus includes both early-stage and advanced manifestations of these conditions.
ALS Research
The investigator conducts extensive research into innovative therapeutic approaches for ALS, exploring various treatment modalities including immunotherapy and novel pharmaceutical compounds.
- Symptom Progression Management
- Therapeutic Innovation
- Disease Modification Strategies
Research efforts concentrate on developing treatments that may slow disease progression and improve patient outcomes.
Huntington's Disease Studies
The investigator's work encompasses comprehensive research into Huntington's disease, including studies of both prodromal and early manifest stages of the condition.
- Biomarker Analysis
- Disease Progression Monitoring
- Therapeutic Evaluation
The research includes assessment of novel therapeutic agents targeting specific disease mechanisms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.